Table 2

Important agents currently enrolling patients in clinical trials for systemic lupus erythematosus as of November 2010

Target

Trial

Comment


T cells

NCT007744752

Abatacept

NCT00774943

Amgen 557 ICOS inhibitor

B cells

NCT00660881

Epratuzumab (anti-CD22)

NCT00624338

Atacicept blocks BlyS and APRIL

NCT01162681

A-623 blocks BlyS and APRIL

NCT01205348

LY2127399 blocks BlyS

Toleragen

NCT01085097

Laquinomod

NCT01135459

Lupuzor tolerizes splicosome

Innate immunity

NCT00962832

Rontalizumab inhibits IFN-α

NCT01164917

Amgen 811 targets IFN-γ

NCT00960362

NNCO152 targets IFN-α

NCT01031836

MEDI-545 targets IFN-α

Cell surface receptor

NCT0077194

Rapamycin targets mTOR


aICOS, ; BlyS, B lymphocyte stimulation; APRIL, ; mTOR (mammalian target of rapamycin).

Wallace BMC Medicine 2010 8:77   doi:10.1186/1741-7015-8-77

Open Data